Pacific Edge (ASX:PEB) has announced the successful completion of a commercial agreement with Te Whatu Ora - Southern for the use of their non-invasive Cxbladder genomic biomarker tests.
Cxbladder is a urine test optimized for the detection and management of bladder cancer, and is reimbursed by CMS and available to 70% of the population in New Zealand via public healthcare.
It has been trusted by over 2,000 US urologists and used in the diagnosis and management of more than 80,000 patients.